Message from the Regulators: Pharmacovigilance to Move Heavily into Risk-Benefit Assessment
Pilar Carrero Director of Safety Medical Writing at Novo Nordisk, joins Andrea Charles from Pharma IQ, to discuss the impact social media has had on drug safety and risk managment and the dawn of a new era for pharmacovigilance. Carrero also shares her insights on optimising pharmacovigilance activities and complying with the Development Safety Update Report (DSUR).
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.